Nonclinical safety assessment for the sensitizing potential of K-115-Reference-Cited by-同舟云学术

Nonclinical safety assessment for the sensitizing potential of K-115

Published:2014 Issue:1 Volume:1 Page:19-27
ISSN:2189-115X
Container-title:Fundamental Toxicological Sciences
language:en
Short-container-title:Fundam. Toxicol. Sci.

Author:

Omichi Kozo¹,Wato Eiji²,Kaneko Yoshiki³,Yoneyama Shigeki⁴,Matsuda Akitaka⁴,Sasaki Mikio⁴,Bull Adrian⁵,Coleman David⁵,Kagawa Masataka²,Amano Yukinori²

Affiliation:

1. Xenobiotics Group, Fuji Research Laboratories, Kowa Company, Ltd.

2. Toxicology Group, Fuji Research Laboratories, Kowa Company, Ltd.

3. Pharmacology Group, Tokyo New Drug Research Laboratories, Kowa Company, Ltd.

4. Ina Research Inc.

5. Huntingdon Life Science, Ltd., UK

Publisher

Japanese Society of Toxicology

Link

https://www.jstage.jst.go.jp/article/fts/1/1/1_19/_pdf

Reference26 articles.

1. Bartlett, M.S. (1937): Properties of sufficiency and statistical tests. Proceedings of the Royal Society. Series A, 160, 268-282. (Also see J.R. Stat. Soc. Suppl. 4, published later)

2. Basketter, D.A., Lea, L.J., Dickens, A., Briggs, D., Pate, I., Dearman, R.J. and Kimber, I. (1999): A comparison of statistical approaches to the derivation of EC3 values from local lymph node assay dose responses. J. Appl. Toxicol., 19, 261-266.

3. Bourke, J., Coulson, I. and English, J. (2009): Guidelines for the management of contact dermatitis: an update. Br. J. Dermatol., 160, 946-954.

4. Draize, J.H. (1959): Dermal toxicity. In: Appraisal of the safety of chemicals in foods, drugs and cosmetics. Austin 1. Texas: The Association of Food and Drug Officials of the United States, 46-59.

5. Dunnett, C.W. (1955): A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc., 50, 1096-1121.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparation and characterization of astaxanthin-loaded biodegradable polyhydroxybutyrate (PHB) microbeads for personal care and cosmetic applications;International Journal of Biological Macromolecules;2024-02

2. Long-term Side Effects Including Blepharitis Leading to Discontinuation of Ripasudil;Journal of Glaucoma;2019-04

3. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma;Expert Opinion on Pharmacotherapy;2017-09-14

4. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy;Graefe's Archive for Clinical and Experimental Ophthalmology;2017-07-15

5. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension;Acta Ophthalmologica;2015-09-04